Intimation of Transcript of Q4 FY 25 for the Earnings Conference Call held on April 28, 2025.
ROSSARI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Rossari Biotech reported FY25 revenue of Rs. 2,080 crore, up 13.6% YoY, crossing the Rs. 2,000 crore milestone for the first time. Q4 FY25 revenue grew 22.6% YoY to Rs. 579.6 crore, while full-year EBITDA rose 6.1% to Rs. 265.1 crore with margins at 12.7% (down from 13.6% in FY24) due to investments in new Institutional and B2C verticals, which themselves grew 67% to Rs. 299 crore. The core business (excluding new verticals) maintained a healthy 15% adjusted EBITDA margin. The Board approved a fresh CAPEX of Rs. 192 crore across Unitop, Tristar, and Rossari sites, with commissioning expected in phases by Q4 FY26. The Board recommended a dividend of Rs. 0.50 per share. Net debt stood at Rs. 70 crore and is expected to roughly double with the new capex.
Management guided core business EBITDA margins of 14.5–15% and overall consolidated margins of 13–13.5% for FY26, with FY27 flagged as a 'much better year' once all capex, EO availability, and consumer business breakeven align. Near-term, margin pressure from upfront investments in B2C/Institutional businesses remains, but the growth capex pipeline and strong export momentum (27% YoY) support a constructive medium-term outlook for shareholders.